Kairos Pharma, Ltd.
KAPA
$1.65
-$0.01-0.60%
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 798.00K | 1.01M | 877.00K | 827.00K | 960.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.42M | 1.69M | 1.42M | 1.44M | 1.46M |
| Operating Income | -1.42M | -1.69M | -1.42M | -1.44M | -1.46M |
| Income Before Tax | -1.39M | -1.65M | -1.37M | -1.40M | -1.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.39M | -1.65M | -1.37M | -1.40M | -1.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.39M | -1.65M | -1.37M | -1.40M | -1.42M |
| EBIT | -1.42M | -1.69M | -1.42M | -1.44M | -1.46M |
| EBITDA | -1.40M | -1.65M | -1.38M | -1.40M | -1.42M |
| EPS Basic | -0.45 | -0.55 | -0.46 | -0.48 | -0.58 |
| Normalized Basic EPS | -0.28 | -0.34 | -0.29 | -0.30 | -0.36 |
| EPS Diluted | -0.45 | -0.55 | -0.46 | -0.48 | -0.58 |
| Normalized Diluted EPS | -0.28 | -0.34 | -0.29 | -0.30 | -0.36 |
| Average Basic Shares Outstanding | 3.06M | 3.00M | 2.98M | 2.89M | 2.46M |
| Average Diluted Shares Outstanding | 3.06M | 3.00M | 2.98M | 2.89M | 2.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |